Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500
Buy Report

Published: March 31, 2022 Report Code: GMDGDHC22026TDB-ST

Select Item

Tyrosine Protein Kinase JAK2 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key MoA in the Tyrosine Protein Kinase JAK2 Pipeline Market

The key MoA in the Tyrosine Protein Kinase JAK2 pipeline market is Tyrosine Protein Kinase JAK2 Inhibitor.

Key RoA in the Tyrosine Protein Kinase JAK2 Pipeline Market

The key RoA in the Tyrosine Protein Kinase JAK2 pipeline market are oral, topical, cutaneous, ophthalmic, inhalational, and intravitreal. Oral has the highest pipeline products.

Tyrosine Protein Kinase JAK2 Pipeline Market, by RoA

Tyrosine Protein Kinase JAK2 Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Tyrosine Protein Kinase JAK2 Pipeline Market

The key molecule type in the Tyrosine Protein Kinase JAK2 pipeline market is small molecule.

Key Companies in the Tyrosine Protein Kinase JAK2 Pipeline Market

The key companies in the Tyrosine Protein Kinase JAK2 pipeline market are Incyte Corp, Japan Tobacco Inc, Kinaset Therapeutics Inc, Merck & Co Inc, Novartis AG, NS Pharma Inc, and OHM Oncology. Incyte Corp has the highest pipeline products.

Tyrosine Protein Kinase JAK2 Pipeline Market, by Companies

Tyrosine Protein Kinase JAK2 Pipeline Market, by Companies

To know about more key companies, download a free report sample

Market report overview

Key MoA Tyrosine Protein Kinase JAK2 Inhibitor
Key RoA Oral, Topical, Cutaneous, Ophthalmic, Inhalational, and Intravitreal
Key molecule type Small Molecule
Key companies Incyte Corp, Japan Tobacco Inc, Kinaset Therapeutics Inc, Merck & Co Inc, Novartis AG, NS Pharma Inc, and OHM Oncology

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects.
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Bristol-Myers Squibb Co
Chengdu Zenitar Biomedical Technology Co Ltd
Concert Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
CTI BioPharma Corp
Eli Lilly and Co
Hangzhou East China Pharmaceutical Group Co Ltd
HK inno.N Corp
Incyte Corp
Japan Tobacco Inc
Kinaset Therapeutics Inc
Merck & Co Inc
Novartis AG
NS Pharma Inc
OHM Oncology
Pfizer Inc
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Sierra Oncology Inc
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Theravance Biopharma Inc
Turning Point Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Overview

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Chengdu Zenitar Biomedical Technology Co Ltd

Concert Pharmaceuticals Inc

Cothera Bioscience Pty Ltd

CTI BioPharma Corp

Eli Lilly and Co

Hangzhou East China Pharmaceutical Group Co Ltd

HK inno.N Corp

Incyte Corp

Japan Tobacco Inc

Kinaset Therapeutics Inc

Merck & Co Inc

Novartis AG

NS Pharma Inc

OHM Oncology

Pfizer Inc

Shanghai Xunhe Pharmaceutical Technology Co Ltd

Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

Sierra Oncology Inc

Simcere Pharmaceutical Group Ltd

Sino Biopharmaceutical Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

Theravance Biopharma Inc

Turning Point Therapeutics Inc

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Drug Profiles

A-223 – Drug Profile

Product Description

Mechanism Of Action

baricitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

CHZ-868 – Drug Profile

Product Description

Mechanism Of Action

CJ-15314 – Drug Profile

Product Description

Mechanism Of Action

History of Events

delgocitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

deuruxolitinib phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

fedratinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

filgotinib maleate – Drug Profile

Product Description

Mechanism Of Action

FLLL-12 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ilginatinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

jaktinib hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

MA-2014 – Drug Profile

Product Description

Mechanism Of Action

momelotinib dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

OB-756 – Drug Profile

Product Description

Mechanism Of Action

OHM-581 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Opzelura – Drug Profile

Product Description

Mechanism Of Action

History of Events

pacritinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

repotrectinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

ruxolitinib phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

SAR-317461 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestinal Tract Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK2 for Autoimmune Disorders and Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit JAK2 for Leukemia – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit BRD4 and JAK2 for Myelofibrosis – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 and FLT3 for Myelofibrosis and Acute Myeloid Leukemia – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 for Inflammation and Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK2 for Myelofibrosis – Drug Profile

Product Description

Mechanism Of Action

Small Moleucle to Inhibit JAK 1 and JAK 2 for Inflammation – Drug Profile

Product Description

Mechanism Of Action

History of Events

TQ-05105 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VR-588 – Drug Profile

Product Description

Mechanism Of Action

History of Events

zotiraciclib citrate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Dormant Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Discontinued Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) – Product Development Milestones

Featured News & Press Releases

Mar 07, 2022: Another lifesaving COVID-19 drug identified

Mar 04, 2022: VONJO (pacritinib) now approved for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 x 109/L

Mar 01, 2022: DRI Healthcare Trust comments on FDA approval of VONJOTM (pacritinib)

Feb 28, 2022: CTI BioPharma announces FDA accelerated approval of VONJO (pacritinib) for the treatment of adult patients with Myelofibrosis and Thrombocytopenia

Feb 17, 2022: Zai Lab announces breakthrough therapy designation granted for Repotrectinib in China

Feb 17, 2022: WHO recommends Baricitinib for Covid-19

Jan 28, 2022: Updates on OLUMIANT (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis

Jan 25, 2022: Sierra Oncology provides financial update to support the future commercialization of momelotinib

Jan 25, 2022: Sierra Oncology announces momelotinib achieved statistically significant benefit on symptoms, anemia and splenic size in the pivotal MOMENTUM study for myelofibrosis

Jan 19, 2022: Momelotinib review article published in Journal of Hematology & Oncology highlights importance of anemia benefit for Myelofibrosis Patients

Jan 18, 2022: Sierra Oncology updates topline data timing for pivotal phase 3 trial of momelotinib in myelofibrosis

Jan 17, 2022: MSF responds to latest WHO recommendation for COVID-19 medicine baricitinib

Jan 14, 2022: WHO recommends Eli Lilly drug to treat COVID-19

Jan 04, 2022: Concert Pharmaceuticals completes enrollment in THRIVE-AA2 phase 3 clinical trial evaluating CTP-543 for Alopecia Areata

Dec 14, 2021: Incyte announces acceptance and Priority Review of sNDA for ruxolitinib cream (Opzelura) as a treatment for patients with vitiligo

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Indications, 2022 (Contd..4)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Chengdu Zenitar Biomedical Technology Co Ltd, 2022

Pipeline by Concert Pharmaceuticals Inc, 2022

Pipeline by Cothera Bioscience Pty Ltd, 2022

Pipeline by CTI BioPharma Corp, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022

Pipeline by HK inno.N Corp, 2022

Pipeline by Incyte Corp, 2022

Pipeline by Japan Tobacco Inc, 2022

Pipeline by Kinaset Therapeutics Inc, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Novartis AG, 2022

Pipeline by NS Pharma Inc, 2022

Pipeline by OHM Oncology, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022

Pipeline by Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd, 2022

Pipeline by Sierra Oncology Inc, 2022

Pipeline by Simcere Pharmaceutical Group Ltd, 2022

Pipeline by Sino Biopharmaceutical Ltd, 2022

Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022

Pipeline by Theravance Biopharma Inc, 2022

Pipeline by Turning Point Therapeutics Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Dormant Products, 2022 (Contd..4)

Dormant Products, 2022 (Contd..5)

Dormant Products, 2022 (Contd..6)

Discontinued Products, 2022

Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently asked questions

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

Most Popular
$7,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Other Diseases reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more